Tivozanib

FOTIVDA is indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for: FOTIVDA is indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.

Side effects, and when to stop

The following clinically significant adverse reactions are also described elsewhere in the labeling:

Hypertension and Hypertensive Crisis
Cardiac Failure
Cardiac Ischemia and Arterial Thromboembolic Events
Venous Thromboembolic Events
Hemorrhagic Events
Proteinuria
Gastrointestinal Perforation and Fistula Formation
Thyroid Dysfunction
Risk of Impaired Wound Healing
Reversible Posterior Leukoencephalopathy Syndrome (RPLS)

Who should not take it

None.

Storing it

Storage and Handling

Store at 20 ° C to 25 ° C (68 ° F to 77 ° F); excursions permitted between 15°C to 30 ° C (59°F to 86 ° F).

Keep out of reach of children.

Cite this page

NLM: sofidex [Internet]. Daloreum; c2026. Tivozanib; [reviewed 2026 Aug 3; cited 2026 Nov 11]. Available from: https://sofidex.com/patients/medicines/tivozanib
APA 7th: sofidex. (2026, August 3). Tivozanib. Daloreum. Retrieved November 11, 2026, from https://sofidex.com/patients/medicines/tivozanib
AMA 11th: Tivozanib. sofidex. Reviewed August 3, 2026. Accessed November 11, 2026. https://sofidex.com/patients/medicines/tivozanib

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.